The emergence of EPKINLY (epcoritamab) as a groundbreaking therapeutic agent has ushered in a new era of precision immunotherapy for patients battling advanced diffuse large B-cell lymphoma. This therapeutic advancement represents the culmination of decades of immunological research translated into a life-saving treatment option for patients with the most challenging forms of this...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek